In diseases like AMD and diabetic retinopathy, where abnormal angiogenesis can lead to vision impairment, targeting both PI3K and VEGF pathways has been explored as a therapeutic strategy [72]. The gene discussed is VEGFA; the disease is diabetic retinopathy.